中国国际金融股份有限公司 关于上海奕瑞光电子科技股份有限公司 增加 2023 年度日常关联交易预计额度的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为上海奕瑞光 电子科技股份有限公司（以下简称"奕瑞科技"或"公司"）的持续督导保荐机构，根据《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易 所上市公司自律监管指引第 5 号——交易与关联交易》等相关法律、法规和规范性文件 的规定，对公司 2023 年度日常关联交易预计事项进行了核查，具体情况如下： 一、日常关联交易基本情况 为了满足业务发展和生产经营的需要，公司拟向成都奕康真空电子技术有限责任公 司（以下简称"成都奕康"、"关联人"）采购直线加速器及其核心部件，拟增加与成都奕 康 2023 年度日常性关联交易额度，具体情况如下： 单位：万元 | | | 原预计 | 本次拟增 | 本次增加 | 增加后占 | 本年年初 至8月29日 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 关联 | 关 | 2023年度 | | | ...

上海奕瑞光电子科技股份有限公司独立董事 关于对公司第二届董事会第二十一次会议相关事项的事前认可意见 章成 高永岗 2023 年 8月28日 （以下无正文，为《上海奕瑞光电子科技股份有限公司独立董事关于对公司第二 届董事会第二十一次会议相关事项的事前认可意见》之签署页) 独立董事签字: 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《关于在上市公 司建立独立董事制度的指导意见》、《上海证券交易所科创板股票上市规则》《上 市公司治理准则》以及《上海奕瑞光电子科技股份有限公司章程》等有关规定, 作为上海奕瑞光电子科技股份有限公司（简称"公司")的独立董事,经认真审 阅《关于增加 2023 年度日常性关联交易预计额度的议案》及相关材料，基于独 立判断的立场，发表如下事前认可意见: 我们认为,《关于增加 2023年度日常性关联交易预计额度的议案》所述增加 2023 年度日常性关联交易预计额度符合公司经营业务的发展需要, 价格参照市 场定价协商制定，是一种公允、合理的定价方式,符合交易当时法律、法规的规 定以及交易当时公司的相关制度，且有利于公司的研发、生产经营及长远发展, 未损害公司及其他非关联方的利益，同意 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 440,366,786.18, representing a year-on-year increase of 34.77%[4] - The net profit attributable to shareholders of the listed company was RMB 136,722,692.11, up 35.50% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 146,761,605.91, reflecting a growth of 31.44% year-on-year[4] - The basic earnings per share for the period was RMB 1.88, an increase of 35.25% compared to the previous year[4] - Total operating revenue for Q1 2023 reached RMB 440,366,786.18, a 34.7% increase from RMB 326,755,752.83 in Q1 2022[17] - Net profit attributable to shareholders of the parent company for Q1 2023 was RMB 136,722,692.11, compared to RMB 100,905,629.04 in Q1 2022, reflecting a 35.5% increase[20] - Basic earnings per share for Q1 2023 was RMB 1.88, up from RMB 1.39 in Q1 2022[20] - The company reported a total comprehensive income of RMB 131,905,062.35 for Q1 2023, up from RMB 100,274,821.35 in Q1 2022[20] Assets and Liabilities - The total assets at the end of the reporting period were RMB 5,930,610,565.85, a 1.92% increase from the end of the previous year[5] - As of March 31, 2023, the total current assets amounted to approximately CNY 4.30 billion, a decrease of 5.02% from CNY 4.53 billion as of December 31, 2022[14] - The total non-current assets reached CNY 1.63 billion, an increase of 26.36% from CNY 1.29 billion at the end of 2022[15] - The total assets of the company stood at CNY 5.93 billion, up from CNY 5.82 billion, indicating a growth of 1.89%[15] - Total liabilities as of Q1 2023 amounted to RMB 1,885,726,049.44, a decrease from RMB 1,915,035,384.37 in the previous year[17] - Current liabilities decreased to CNY 476.56 million, down 8.85% from CNY 523.01 million[16] - Short-term borrowings were reported at CNY 117.21 million, a decrease of 10.66% from CNY 130.68 million[16] - The company’s accounts payable decreased to CNY 196.42 million, down 8.25% from CNY 214.14 million[16] Cash Flow - The net cash flow from operating activities was negative RMB 41,075,090.80, a decline of 222.39% compared to the previous year[4] - Cash received from sales of goods and services in Q1 2023 was RMB 282,179,691.65, down from RMB 326,452,247.44 in Q1 2022[20] - The net cash flow from operating activities was -41,075,090.80, a decrease from 33,561,830.69 in the previous year[21] - Cash inflow from investment activities totaled 167,789,291.67, down from 390,510,801.34 year-over-year[21] - The net cash flow from investment activities was -171,300,180.02, compared to a positive 72,525,674.42 in the previous year[21] - Cash outflow from financing activities amounted to 2,339,351.97, an increase from 276,151.99 in the previous year[22] - The net increase in cash and cash equivalents was -217,910,030.63, contrasting with an increase of 106,707,347.76 in the previous year[22] - The ending balance of cash and cash equivalents was 2,487,573,399.91, compared to 1,531,852,569.53 in the previous year[22] Research and Development - Research and development expenses totaled RMB 57,527,080.59, accounting for 13.06% of operating revenue, a decrease of 2.98 percentage points year-on-year[5] - Research and development expenses for Q1 2023 totaled RMB 57,527,080.59, an increase from RMB 52,428,212.05 in Q1 2022[18] Shareholder Information - The top ten shareholders held a total of 60.57% of the company's shares, with the largest shareholder owning 16.39%[10] - Total equity attributable to shareholders of the parent company increased to RMB 4,019,630,086.72 from RMB 3,876,720,466.15 year-over-year[17] Government Subsidies - The company received government subsidies related to its normal business operations, totaling RMB 4,570,754.67 for rent and RMB 4,424,778.76 for shipment subsidies[7] Other Information - The company has not disclosed any significant new product developments or market expansion strategies during this reporting period[13] - There are no notable mergers or acquisitions reported in the current quarter[13] - Other comprehensive income after tax for Q1 2023 was RMB -3,074,999.16, compared to RMB -991,380.97 in Q1 2022[20] - The company recorded cash outflow for purchasing goods and services at 202,198,792.26, an increase from 195,862,766.33 year-over-year[21]

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2023-039 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 上海奕瑞光电子科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 10 日（星期三）至 5 月 16 日（星期二）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （ir@iraygroup.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海奕瑞光电子科技股份有限公司（以下简称"公司"）分别于 2023 年 3 月 17 日、2023 年 4 月 27 日在上海证券交易所网站（www.sse.com.cn）披露了《2022 年年度报告》《2023 年第一季度报告》，为便于广大投资者更全面深入地了解公 司的经营成果、财务状 ...

Dividend and Share Capital - The company plans to distribute a cash dividend of 29.00 CNY per 10 shares, totaling approximately 210.81 million CNY, which represents 32.87% of the net profit attributable to shareholders [2]. - The company intends to increase its total share capital by 4 shares for every 10 shares held, resulting in an increase of approximately 29.08 million shares, raising the total share capital to approximately 101.77 million shares [2]. - The company has established a cash dividend policy that aligns with its articles of association and shareholder return plan for 2022-2024 [189]. Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion in 2022, representing a year-over-year growth of 25% [12]. - The operating revenue for 2022 was CNY 1,549,116,657.78, reflecting a growth of 30.47% year-on-year, driven by rapid sales growth in dental and industrial products [21]. - The net profit attributable to shareholders was CNY 641,300,445.36, up 32.49% from the previous year, while the net profit after deducting non-recurring gains and losses increased by 51.18% to CNY 516,793,469.55 [21]. - Basic earnings per share rose to CNY 8.84, a 32.53% increase year-on-year, supported by the growth in net profit [21]. - The net cash flow from operating activities was CNY 316,620,618.89, an increase of 27.66% compared to the previous year, attributed to higher sales receipts [21]. Research and Development - The company has invested RMB 200 million in R&D for new technologies, focusing on improving the efficiency of X-ray imaging systems [12]. - The company's R&D investment accounted for 15.41% of operating revenue, an increase of 3.14 percentage points from the previous year [20]. - Research and development expenses increased by 63.87% to RMB 239 million, driven by enhanced R&D team construction and investment [112]. - The company applied for 66 new intellectual property rights during the reporting period, including 37 invention patent applications, and has a total of 398 registered or authorized IP rights [75][76]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2023 [12]. - A strategic acquisition of a local competitor is anticipated to be finalized in Q3 2023, which is expected to increase the company's market share by 10% [12]. - The company aims to develop comprehensive solutions that integrate hardware, software, and applications to improve overall service offerings [37]. - The company plans to deepen cooperation with strategic clients and expand market share in medical and industrial sectors, enhancing global customer relationships [142]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm [2]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy [2]. - The company has established a comprehensive governance structure to ensure compliance with legal and regulatory standards [147]. - The company’s board of directors included independent members, ensuring compliance with governance standards [175]. Risks and Challenges - The company faces risks related to intellectual property protection and potential technology leaks, which could negatively impact its competitive edge and operational performance [92]. - There is a risk of falling behind in technology and product development if the company fails to respond to revolutionary new technologies in the market [93]. - The company relies on a concentrated supply chain for key raw materials, with over 20% sourced from overseas, which poses risks if suppliers fail to deliver [95]. - The company is at risk of slower market demand and potential inability to digest new production capacity, which could affect overall business performance [109]. Employee and Management - The total number of employees has exceeded 1,200, with over 400 in R&D, representing a year-on-year growth of 57% and 59% respectively, enhancing the company's talent pool [34]. - The company has implemented an employee stock incentive plan, granting shares to 263 employees to enhance motivation and retention [186]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 7.9187 million RMB [171]. - The company is focused on attracting and retaining high-quality talent to support its growth and innovation strategies [144]. Product Development and Innovation - New product development includes the launch of a next-generation Flat Panel Detector, expected to enhance imaging quality by 30% compared to previous models [11]. - The company has developed a high-performance readout chip for digital X-ray detectors, achieving commercial mass production and reaching international product performance levels [66]. - The company has completed the development of core components for CT detectors, including collimators, scintillators, and photodiodes, and is focused on achieving full integration of CT detectors [64]. - The company has developed several types of flat panel detectors and line array detectors to meet diverse market needs in the dental and industrial sectors [58]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting the success of recent service enhancements [159]. - The company is exploring partnerships with local firms to strengthen its supply chain and distribution networks [157]. - The company aims to enhance its customer engagement strategies, aiming for a 40% increase in customer retention rates [163]. Future Outlook - The company provided guidance for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion [159]. - Future trends in digital X-ray detectors include advancements towards lower radiation doses, real-time imaging, and 3D rendering capabilities [60]. - The company is actively investing in new product development and technological advancements to maintain competitive advantage [154].

Financial Performance - The company's operating revenue for Q3 2022 was ¥383,276,626.22, representing a year-on-year increase of 42.97%[4] - The net profit attributable to shareholders for Q3 2022 was ¥231,526,234.32, a significant increase of 99.43% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥130,625,864.94, up 44.50% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥3.19, reflecting a 99.38% increase compared to the same period last year[5] - Total operating revenue for the first three quarters of 2022 reached ¥1,103,884,316.02, a significant increase of 34.0% compared to ¥823,730,410.66 in the same period of 2021[20] - The net profit for the first three quarters was ¥561,854,362.02, compared to ¥358,889,323.20 in the same period last year, indicating a growth of 56.5%[22] - The total profit amounted to ¥561,982,700.45, an increase from ¥366,111,337.92 year-over-year[24] - Net profit reached ¥507,419,621.64, compared to ¥326,875,061.52 in the previous year, reflecting a significant growth[24] - Basic and diluted earnings per share were both ¥7.00, up from ¥4.49 in the same quarter last year[26] Research and Development - The total R&D investment for Q3 2022 was ¥58,001,680.90, which accounted for 15.13% of operating revenue, an increase of 1.53 percentage points from the previous year[5] - Research and development expenses for the first three quarters were ¥163,434,194.84, which is an increase of 79.9% compared to ¥90,808,803.93 in the previous year[22] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥4,220,164,645.82, representing a year-on-year increase of 19.31%[5] - Non-current assets totaled ¥1,398,388,625.60, a substantial increase from ¥490,360,841.81 year-over-year[19] - Total assets reached ¥4,220,164,645.82, compared to ¥3,537,103,476.01 in the previous year, marking an increase of 19.4%[19] - Total liabilities increased to ¥754,528,138.53 from ¥460,545,675.63, reflecting a growth of 63.8%[19] - The total equity attributable to shareholders at the end of Q3 2022 was ¥3,440,093,968.87, up 12.71% from the previous year[5] - The company's equity attributable to shareholders rose to ¥3,440,093,968.87, up from ¥3,052,177,549.45, representing an increase of 12.7%[19] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥156,640,447.56, an increase of 48.26% year-on-year[5] - Cash flow from operating activities generated ¥156,640,447.56, an increase from ¥105,654,545.80 year-over-year[28] - The company reported a net cash outflow from investing activities of ¥206,507,584.34, contrasting with a net inflow of ¥729,304,434.04 in the previous year[28] - The company’s total operating cash inflow was ¥1,310,466,150.40, compared to ¥932,536,083.64 in the previous year[27] - The company’s cash flow from financing activities generated a net inflow of ¥41,802,168.77, compared to a net outflow of ¥140,725,364.60 in the previous year[29] Shareholder Information - The top ten unrestricted shareholders hold a total of 44,000,000 shares, with Shanghai Yiyuan He Rui Investment Consulting Co., Ltd. holding 11,915,652 shares, accounting for 16.42% of the total[11] Current Assets - As of September 30, 2022, the company's total current assets amounted to approximately ¥2.82 billion, a decrease from ¥3.05 billion at the end of 2021, reflecting a decline of about 7.4%[17] - The company's cash and cash equivalents increased to ¥1.45 billion from ¥1.42 billion year-over-year, showing a slight growth of 1.2%[17] - Inventory levels rose significantly to ¥579.61 million, up from ¥329.62 million, indicating an increase of approximately 75.7%[17] - The company's receivables from accounts decreased slightly to ¥281.14 million from ¥281.49 million, a marginal decline of about 0.1%[17] - The total amount of financial assets held for trading decreased to ¥384.94 million from ¥835.60 million, representing a decline of approximately 54%[17] - The company reported an increase in other receivables to ¥50.60 million from ¥17.76 million, marking a significant rise of about 185%[17] Market and Product Development - The report does not indicate any significant new product developments or technological advancements during the quarter[15] - There are no updates on market expansion or mergers and acquisitions in the current report[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[19] Miscellaneous - The company has not participated in margin financing or securities lending activities, and the status of unrestricted shareholders' participation in such activities is unknown[14]

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a year-on-year increase of 20%[6]. - The company reported a significant increase in revenue, achieving a total of RMB 500 million for the first half of 2022, representing a 25% year-over-year growth[12]. - The company's operating revenue for the first half of 2022 was RMB 720,607,689.80, representing a year-on-year increase of 29.69%[16]. - The net profit attributable to shareholders for the same period was RMB 276,446,388.79, up 31.80% year-on-year, while the net profit after deducting non-recurring gains and losses increased by 54.21% to RMB 274,852,743.22[16]. - Basic earnings per share for the first half of 2022 were RMB 3.81, a 31.83% increase compared to the same period last year[17]. - The total comprehensive income for the first half of 2022 was approximately ¥275.24 million, compared to ¥208.64 million in the first half of 2021, marking a 32% increase[168]. - The company reported a foreign exchange loss of approximately ¥2.49 million in the first half of 2022, compared to a loss of ¥2.11 million in the same period of 2021[168]. - The company experienced a credit impairment loss of approximately ¥18.44 million in the first half of 2022, compared to a loss of ¥9.94 million in the same period of 2021[171]. Market Expansion and Product Development - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% compared to the first half[6]. - New product launches include the iRay X1 imaging system, which is expected to contribute an additional 100 million CNY in revenue by the end of 2022[6]. - The company is expanding its market presence in Europe, targeting a 30% increase in sales in that region by the end of 2022[6]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[12]. - New product development includes the launch of a next-generation flat panel detector, expected to enhance imaging quality and reduce radiation exposure by 30%[12]. - The company plans to increase its production capacity by 40% in response to rising demand for its products[12]. - The company has established partnerships with three major hospitals to pilot new imaging solutions, with initial feedback indicating a 20% improvement in workflow efficiency[12]. Research and Development - Research and development expenses increased by 10% to 50 million CNY, focusing on advanced imaging technologies[6]. - The company has invested RMB 50 million in R&D for new imaging technologies, focusing on AI integration to improve diagnostic accuracy[12]. - The company achieved a total R&D investment of approximately ¥105.43 million, representing a 94.06% increase compared to the previous year[53]. - R&D investment accounted for 14.63% of total operating revenue, an increase of 4.85 percentage points year-on-year[53]. - The company has expanded its R&D team, increasing the number of R&D personnel from 213 to 335, a growth of 57.2%[57]. - The company has filed 36 new intellectual property applications during the reporting period, including 5 invention patent applications[51]. - The total number of intellectual property registrations or authorizations reached 369, including 115 invention patents[51]. Financial Position and Assets - The company's total assets at the end of the reporting period were RMB 3,938,482,330.94, reflecting an 11.35% increase from the end of the previous year[16]. - The company's cash flow from operating activities was 112,680,649.99 CNY, up 24.27% compared to the previous year[89]. - The company's inventory value is 511.1 million yuan, representing 16.25% of current assets, with raw materials making up 59.64% of the inventory[82]. - The company's total liabilities increased to ¥715,569,958.88 from ¥460,545,675.63, which is an increase of approximately 55.4%[162]. - The company's equity attributable to shareholders rose to ¥3,196,183,196.23 from ¥3,052,177,549.45, showing an increase of about 4.7%[162]. Risks and Challenges - The management highlighted potential risks including supply chain disruptions, which could impact future performance[5]. - The company faces risks related to the development of new technologies and products, with a focus on maintaining high R&D investment ratios[74]. - The company is exposed to exchange rate risks, particularly with significant foreign currency transactions impacting profitability[81]. - The company has a risk of core technology leakage due to reliance on proprietary technology and supplier relationships[73]. - The company faces risks from potential adverse changes in healthcare policies in China and developed countries, which could impact demand for digital X-ray detectors[84]. Corporate Governance and Compliance - There were no significant changes in corporate governance or special arrangements reported during this period[5]. - The company has received multiple quality management certifications, including EN ISO13485:2016 and FDA registration, ensuring its products meet high international standards[63]. - The company has established a quality management system compliant with international standards, ensuring product safety and effectiveness[72]. - The company has committed to maintaining a minimum share price for any potential share reductions after the lock-up period[111]. - The company has established measures to avoid and reduce related party transactions, ensuring that transactions are conducted at market prices and do not harm the company's interests[128]. Shareholder Commitments and Stock Management - The company has committed to a share lock-up period of 36 months for its actual controllers and major shareholders following its IPO[110]. - The company will ensure compliance with the Shanghai Stock Exchange regulations throughout the lock-up period[112][113][114]. - The company has established a three-year dividend return plan post-listing to ensure shareholder returns[121]. - The company will actively promote cash dividends to shareholders when profit distribution conditions are met[121]. - The commitments made by shareholders include a promise to not reduce their holdings during the specified periods[130]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions, including optimizing processes and improving material and equipment utilization to lower energy consumption[107]. - The company has actively promoted environmental protection through training and awareness programs, ensuring compliance with environmental regulations[106]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[105]. - The company has taken steps to improve waste reduction through process improvements and material recycling[106].

Financial Performance - The company achieved operating revenue of ¥326,755,752.83, representing a year-on-year increase of 46.27%[4] - Net profit attributable to shareholders was ¥100,905,629.04, up 35.47% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥111,655,846.83, reflecting a growth of 65.10%[4] - Basic earnings per share were ¥1.39, representing an increase of 34.95%[4] - Total revenue for Q1 2022 reached ¥326,755,752.83, a significant increase of 46.4% compared to ¥223,385,289.90 in Q1 2021[16] - Net profit for Q1 2022 was ¥101,266,202.32, representing a 33.6% increase from ¥75,785,104.37 in Q1 2021[17] - The net profit attributable to the parent company's shareholders for Q1 2022 was approximately ¥100.91 million, compared to ¥74.49 million in Q1 2021, representing a year-over-year increase of 35.5%[18] - Total comprehensive income for Q1 2022 was approximately ¥100.27 million, up from ¥74.42 million in Q1 2021, indicating a growth of 34.7%[18] - Basic and diluted earnings per share for Q1 2022 were both ¥1.39, an increase from ¥1.03 in Q1 2021, reflecting a rise of 34.9%[18] Research and Development - Research and development expenses totaled ¥52,428,212.05, marking a significant increase of 119.19% year-on-year[5] - Research and development expenses rose to ¥52,428,212.05, more than double the ¥23,919,510.57 spent in Q1 2021, indicating a strong focus on innovation[17] - The company plans to continue expanding its R&D team and increasing investment in new technologies[9] Cash Flow and Assets - The cash flow from operating activities was ¥33,561,830.69, a decrease of 50.00% compared to the previous year[4] - Cash inflows from operating activities in Q1 2022 totaled approximately ¥362.30 million, compared to ¥298.07 million in Q1 2021, marking an increase of 21.5%[20] - The net cash flow from operating activities for Q1 2022 was approximately ¥33.56 million, down from ¥67.13 million in Q1 2021, showing a decline of 50%[20] - Cash inflows from investment activities in Q1 2022 were approximately ¥390.51 million, significantly higher than ¥205.07 million in Q1 2021, representing an increase of 90.1%[20] - The net cash flow from investment activities for Q1 2022 was approximately ¥72.53 million, a turnaround from a negative cash flow of ¥229.82 million in Q1 2021[20] - The net cash flow from financing activities for Q1 2022 was approximately ¥3.57 million, compared to a negative cash flow of ¥60.07 million in Q1 2021, indicating a significant improvement[21] - The cash and cash equivalents at the end of Q1 2022 amounted to approximately ¥1.53 billion, up from ¥1.11 billion at the end of Q1 2021, reflecting an increase of 37.9%[21] - As of March 31, 2022, the company's cash and cash equivalents amounted to ¥1,531,852,600.06, an increase from ¥1,425,145,252.29 as of December 31, 2021, reflecting a growth of approximately 7.9%[14] - The total current assets decreased slightly to ¥3,038,293,429.05 from ¥3,046,742,634.20, indicating a decline of about 0.3%[14] - The company's inventory increased significantly to ¥431,942,061.85, up from ¥329,622,089.17, representing a growth of approximately 31%[14] - The accounts receivable decreased to ¥227,056,237.43 from ¥281,487,940.45, showing a decline of about 19.3%[14] - The trading financial assets decreased to ¥663,458,274.85 from ¥835,599,514.65, a reduction of approximately 20.6%[14] - Non-current assets totaled ¥687,685,659.88, an increase of 40.2% from ¥490,360,841.81 year-over-year[16] - The total assets at the end of the reporting period were ¥3,725,979,088.93, up 5.34% from the end of the previous year[5] - The total assets of the company reached ¥3,725,979,088.93, up from ¥3,537,103,476.01, marking a growth of 5.3%[16] Liabilities and Equity - Total liabilities amounted to ¥691,209,152.63, up 50.2% from ¥460,545,675.63 in the previous year[16] - The company reported a significant increase in accounts payable, which rose to ¥170,025,436.15 from ¥120,245,617.40, reflecting increased operational activity[16] - Deferred income decreased to ¥45,456,456.95 from ¥50,522,920.33, indicating a potential shift in revenue recognition strategies[16] - The company’s equity attributable to shareholders decreased slightly to ¥3,007,165,929.50 from ¥3,052,177,549.45, reflecting changes in retained earnings[16] - The financial report is unaudited, indicating that the figures presented are subject to further verification[14] Shareholder Information - The company reported a total of 10 major shareholders, with Tianjin Sequoia Investment holding 6,300,000 shares, representing 8.68% of the total shares[12] - The company has a significant focus on employee stock ownership platforms, with multiple investment partnerships controlled by the same individuals[12] - The company is actively involved in financing and margin trading, although specific details were not applicable for this report period[12] Future Outlook - The company is expected to continue monitoring its financial health and market strategies in light of the current economic conditions[13] - The company has adopted new accounting standards starting in 2022, which may impact future financial reporting[22]

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion, representing a growth of 25% year-over-year[16]. - The company's operating revenue for 2021 was CNY 1,187,352,896.36, representing a 51.43% increase compared to the previous year[22]. - Net profit attributable to shareholders for 2021 was CNY 484,039,540.68, a 117.79% increase year-over-year[22]. - The basic earnings per share for 2021 was CNY 6.67, up 76.92% from the previous year[24]. - The company achieved operating revenue of 1.187 billion RMB, a year-on-year increase of 51.43%[87]. - The net profit attributable to the parent company was 484 million RMB, representing a year-on-year growth of 117.79%[87]. - Revenue for the year reached $1.5 billion, representing a 15% increase compared to the previous year[139]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in Q3 2023, totaling $500 million[138]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of 22 CNY per 10 shares, totaling approximately 159.61 million CNY, which represents 32.97% of the net profit attributable to ordinary shareholders[5]. - The cash dividend proposal for 2021 is to distribute 22 RMB per 10 shares, totaling approximately 159.61 million RMB, which is 32.97% of the net profit attributable to shareholders[163]. Research and Development - The company is investing RMB 100 million in R&D for new imaging technologies over the next three years[16]. - Research and development expenses accounted for 12.27% of operating revenue in 2021, a slight increase from 12.24% in 2020[23]. - R&D investment amounted to 145.6972 million, accounting for 12.27% of total revenue, with a 58% increase in the number of R&D personnel[30]. - The company has developed a complete technology system for TFT SENSOR design, achieving 25 integrated circuit layout design registrations, demonstrating strong innovation capabilities compared to competitors who purchase standard products[52]. - The company has successfully mass-produced non-spliced CMOS detectors and is developing CMOS chips and detectors for vascular imaging, with performance comparable to imported products[53]. - The company is focusing on low radiation dose, real-time imaging, and intelligent solutions in its product development[114]. - Research and development investments have increased by 40%, focusing on advanced technologies and product enhancements[141]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a market share increase of 15% within the next two years[16]. - The company is actively exploring new core components and materials for X-ray imaging equipment, achieving progress in areas such as ceramic scintillators and high-voltage generators[36]. - The company is focusing on expanding its market presence and is actively pursuing new strategies for growth, including potential mergers and acquisitions[132]. - The company aims to enhance its global sales and service network to increase market share[115]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[139]. Risk Management - The company has detailed potential risks in the "Management Discussion and Analysis" section of the report[4]. - The company faces risks related to the fluctuation of raw material prices, particularly in the semiconductor sector, which could affect product cost control and overall profitability[76]. - The company has a reliance on specific foreign suppliers for key components, and any disruption in supply could adversely affect production operations[76]. - Changes in medical industry policies in key markets could adversely affect demand for the company's digital X-ray detectors, impacting business growth and profitability[82]. Corporate Governance - The audit report issued by the accounting firm is a standard unqualified opinion[4]. - The company has not disclosed any special arrangements for corporate governance[7]. - The company has maintained a stable governance structure with no significant changes in the board composition during the reporting period[136]. - The company has appointed several independent directors and executives with extensive experience in finance and management[136]. Employee and Talent Management - The company has implemented a stock incentive plan for 210 employees to enhance talent retention and motivation[33]. - The workforce grew to 788 employees, with R&D personnel increasing by 58.02% to 256[33]. - The company has established a comprehensive customer service system, providing 24/7 support globally, which has significantly reduced product repair cycles and gained widespread recognition[72]. - The company aims to attract and retain talent through a comprehensive compensation policy that includes fixed salaries, performance bonuses, and commissions[159]. Product Development and Innovation - New product development includes the launch of a next-generation digital X-ray detector, expected to enhance imaging quality by 30%[16]. - The company has developed a flexible substrate sensor technology that is lightweight and impact-resistant, suitable for various applications including mobile healthcare and industrial non-destructive testing[53]. - The company has developed three intelligent X-ray detection technologies, including AED automatic detection technology, AEC automatic control technology, and ABS automatic brightness control technology, enhancing the upgrade of old X-ray systems[56]. - The company has established an independent detector physics research department and collaborates with international research institutions to develop algorithms related to optical sensor physical properties, achieving numerous invention patents[57]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, investing in reducing radiation harm through innovative product development[177]. - The company is not listed as a key pollutant discharge unit and has not faced administrative penalties for environmental issues during the reporting period[178]. - The company has established an environmental health and safety management department to oversee compliance with environmental protection regulations[183]. Financial Position and Assets - The company's total assets at the end of 2021 were CNY 3,537,103,476.01, reflecting a 22.16% increase from the end of 2020[22]. - The company's accounts receivable increased by 127.55% to 281,487,940.45 RMB, attributed to sales growth[105]. - Inventory levels rose by 90.54% to 329,622,089.17 RMB, mainly due to an increase in raw material stock[105]. - The company's total liabilities included a significant increase in contract liabilities, which grew by 374.05% to 79,748,994.75 RMB, indicating a rise in advance payments from customers[106].

Revenue and Profitability - Revenue for Q3 2021 reached ¥268,073,020.43, an increase of 58.40% year-over-year[4] - Net profit attributable to shareholders was ¥116,093,504.64, reflecting a 151.27% increase compared to the same period last year[4] - Net profit excluding non-recurring items was ¥90,396,705.14, up 116.88% year-over-year[4] - Basic earnings per share (EPS) was ¥1.60, an increase of 88.24% compared to the previous year[4] - Total operating revenue for the first three quarters of 2021 reached ¥823,730,410.66, a significant increase of 48.6% compared to ¥554,242,569.37 in the same period of 2020[20] - Net profit for the first three quarters of 2021 was ¥326,875,061.52, compared to ¥156,479,419.16 in 2020, representing a growth of 108.7%[20] - The net profit attributable to shareholders of the parent company for Q3 2021 was approximately ¥325.84 million, a significant increase from ¥155.73 million in Q3 2020, representing a growth of 109.1%[21] - The total comprehensive income for Q3 2021 reached approximately ¥321.70 million, compared to ¥154.90 million in Q3 2020, indicating an increase of 107.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,200,415,782.88, a 10.54% increase from the end of the previous year[5] - The total assets as of the end of the third quarter of 2021 were ¥3,200,415,782.88, compared to ¥2,895,365,652.88 at the end of the same period in 2020, showing an increase of 10.5%[18] - Non-current assets totaled ¥301,753,069.90, up from ¥169,418,208.44 in the previous year, marking a 78.2% increase[18] - Total liabilities reached ¥311,285,302.15, compared to ¥261,566,262.05 in 2020, reflecting a 19% increase[18] - Total current assets reached ¥2,898,662,712.98, compared to ¥2,725,947,444.44 at the end of 2020, showing a growth of about 6.3%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥105,654,545.80, down 15.55% year-over-year[4] - Cash inflows from operating activities for the first three quarters of 2021 amounted to approximately ¥932.54 million, compared to ¥720.55 million in the same period of 2020, marking an increase of 29.4%[23] - The net cash flow from operating activities for the first three quarters of 2021 was approximately ¥105.65 million, down from ¥125.11 million in the same period of 2020, a decrease of 15.5%[23] - The cash flow from investing activities for the first three quarters of 2021 was approximately ¥729.30 million, compared to a net outflow of ¥12.86 million in the same period of 2020[24] - The net cash flow from financing activities for Q3 2021 was approximately -¥140.73 million, a decrease from a net inflow of ¥1,996.60 million in Q3 2020[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,019, with the largest shareholder holding 11,915,652 shares, representing 16.42% of total shares[10] - The company has a total of 6,300,000 unrestricted circulating shares held by Tianjin Sequoia Juye Equity Investment Partnership, accounting for 8.68% of total shares[12] - The number of shares held by the top ten unrestricted shareholders includes significant stakes from various investment partnerships, indicating strong institutional interest[12] Research and Development - R&D expenses totaled ¥36,479,223.99, representing 13.62% of revenue, a decrease of 0.68 percentage points year-over-year[5] - Research and development expenses for the first three quarters of 2021 amounted to ¥90,808,803.93, an increase from ¥66,563,711.45 in the previous year, indicating a 36.3% rise[20] Other Information - The company reported a significant increase in net profit due to growth in sales volume and increased financial income[8] - Non-recurring gains included government subsidies amounting to ¥21,736,228.13 for the quarter[6] - The company has not disclosed any new product developments or market expansion strategies in the current reporting period[14] - There are no significant changes in the shareholder structure or related party transactions reported for this period[13]